An increase in the endogenous MMP inhibitor TIMP-1 was detected in patients with multiple myeloma, which may account for the reduction in MMP-7 activity, although it is likely that other mechanisms also contribute. This evidence concerns the gene TIMP1 and plasma cell myeloma.